Summary
Regeneron Pharmaceuticals, Inc. filed an 8-K report detailing the outcomes of its 2017 Annual Meeting of Shareholders held on June 9, 2017. The primary focus of the report is the shareholder approval of several key proposals, including the election of directors, the ratification of its independent auditor, and the adoption of an Amended and Restated Long-Term Incentive Plan. The strong approval of these proposals suggests continued shareholder confidence in the company's governance and executive team. Of particular note for investors is the shareholder approval of the Amended and Restated Regeneron Pharmaceuticals, Inc. 2014 Long-Term Incentive Plan. This plan is crucial for retaining and incentivizing key talent, which is vital for a research-driven biopharmaceutical company like Regeneron. The results of the advisory vote on executive compensation and the frequency of such votes also indicate shareholder alignment with the company's compensation practices.
Key Highlights
- 1Shareholders overwhelmingly elected all nominated directors to serve until their respective terms expire.
- 2PricewaterhouseCoopers LLP was ratified as Regeneron's independent registered public accounting firm for fiscal year 2017 with strong shareholder support.
- 3The Amended and Restated Regeneron Pharmaceuticals, Inc. 2014 Long-Term Incentive Plan was approved by shareholders.
- 4An advisory vote to approve the compensation of the company's named executive officers passed.
- 5Shareholders voted in favor of holding advisory votes on executive compensation every three years.
- 6The company confirmed that it is an emerging growth company and has elected not to use the extended transition period for complying with new or revised financial accounting standards.